• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insiders Buying OPKO Health And 2 Other Penny Stocks

    1/30/24 9:04:04 AM ET
    $OPK
    $RCG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance
    Get the next $OPK alert in real time by email

    The Dow Jones index closed higher by more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    OPKO Health

    • The Trade: OPKO Health, Inc. (NASDAQ:OPK) Director Richard Krasno acquired a total of 30,000 shares an average price of $0.99. To acquire these shares, it cost around $29,838.
    • What’s Happening: OPKO Health recently priced private offering of $200 million convertible senior notes due 2029.
    • What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.

    Butler National

    • The Trade: Butler National Corporation (OTC:BUKS) 10% owner Joseph Patrick Daly acquired a total of 900 shares at at an average price of $0.73. To acquire these shares, it cost around $657.
    • What’s Happening: On Nov. 1, Butler National's subsidiary, Avcon Industries, Inc., obtained FAA approval of the Avcon nose extension and the Avcon extra-large "Whale Pod" modifications in the King Air Model B300 Airplanes.
    • What Butler National Does: Butler National Corp is engaged in designing, manufacturing and selling, installing, repairing, modifying, overhauling, servicing and distributing a broad portfolio of aerostructures, aircraft components, avionics, accessories, subassemblies, and systems.

    Check This Out: Alphabet, Microsoft And 3 Stocks To Watch Heading Into Tuesday

    RENN Fund

    • The Trade: RENN Fund, Inc. (NYSE:RCG) President and CEO Murray Stahl acquired a total of 56 shares at an average price of $1.62. The insider spent around $90.72 to buy those shares.
    • What’s Happening: RENN Fund fell around 10% over the past six months.
    • What RENN Fund Does: RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed with the objective of providing long-term capital appreciation by investing substantially in privately placed convertible and equity securities of emerging growth companies traded on the United States securities exchanges.


    Don’t forget to check out our premarket coverage here

    Get the next $OPK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPK
    $RCG

    CompanyDatePrice TargetRatingAnalyst
    OPKO Health Inc.
    $OPK
    11/20/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    10/31/2025$1.60Buy → Hold
    Jefferies
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    OPKO Health Inc.
    $OPK
    12/15/2022$3.00Buy
    H.C. Wainwright
    OPKO Health Inc.
    $OPK
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $OPK
    $RCG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/Co-Portfolio Manager Stahl Murray bought $3,459 worth of shares (1,134 units at $3.05), increasing direct ownership by 0.23% to 155,294 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/17/26 2:30:19 PM ET
    $RCG
    Investment Managers
    Finance

    President/Co-Portfolio Manager Stahl Murray bought $3,459 worth of shares (1,134 units at $3.05), increasing direct ownership by 0.23% to 154,934 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/16/26 12:33:27 PM ET
    $RCG
    Investment Managers
    Finance

    President/Co-Portfolio Manager Stahl Murray bought $3,413 worth of shares (1,134 units at $3.01), increasing direct ownership by 0.23% to 154,574 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/13/26 10:32:01 AM ET
    $RCG
    Investment Managers
    Finance

    $OPK
    $RCG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/Co-Portfolio Manager Stahl Murray bought $3,459 worth of shares (1,134 units at $3.05), increasing direct ownership by 0.23% to 155,294 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/17/26 2:30:19 PM ET
    $RCG
    Investment Managers
    Finance

    President/Co-Portfolio Manager Stahl Murray bought $3,459 worth of shares (1,134 units at $3.05), increasing direct ownership by 0.23% to 154,934 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/16/26 12:33:27 PM ET
    $RCG
    Investment Managers
    Finance

    President/Co-Portfolio Manager Stahl Murray bought $3,413 worth of shares (1,134 units at $3.01), increasing direct ownership by 0.23% to 154,574 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/13/26 10:32:01 AM ET
    $RCG
    Investment Managers
    Finance

    $OPK
    $RCG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    11/20/25 8:08:07 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opko Health downgraded by Jefferies with a new price target

    Jefferies downgraded Opko Health from Buy to Hold and set a new price target of $1.60

    10/31/25 8:18:38 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    4/25/25 8:32:28 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $RCG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

    MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization

    2/27/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

    MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront

    2/26/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

    MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants

    2/12/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $RCG
    SEC Filings

    View All

    SEC Form N-CEN filed by RENN Fund Inc

    N-CEN - RENN Fund, Inc. (0000919567) (Filer)

    3/13/26 11:38:56 AM ET
    $RCG
    Investment Managers
    Finance

    SEC Form N-CSR filed by RENN Fund Inc

    N-CSR - RENN Fund, Inc. (0000919567) (Filer)

    3/9/26 4:07:11 PM ET
    $RCG
    Investment Managers
    Finance

    SEC Form 10-K filed by OPKO Health Inc.

    10-K - OPKO HEALTH, INC. (0000944809) (Filer)

    2/26/26 4:10:02 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $RCG
    Leadership Updates

    Live Leadership Updates

    View All

    OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    9/23/24 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

    NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C

    9/15/22 4:05:00 PM ET
    $OPK
    $TALK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

    OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

    MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.  "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di

    6/22/21 8:00:00 AM ET
    $OPK
    $NVTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $OPK
    $RCG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OPKO Health Inc.

    SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

    SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/12/24 4:54:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $RCG
    Financials

    Live finance-specific insights

    View All

    OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

    MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront

    2/26/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

    MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants

    2/12/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextPlat Reports Third Quarter 2025 Results

    Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026  HALLANDALE BEACH, Fla., Nov. 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced the financial results for the quarter-ended September 30, 2025, reflecting the performance of its e-Commerce and Healthcare Operations.

    11/13/25 8:03:00 AM ET
    $BABA
    $NXPL
    $OPK
    Real Estate
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations